MX2022016516A - Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. - Google Patents
Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso.Info
- Publication number
- MX2022016516A MX2022016516A MX2022016516A MX2022016516A MX2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A MX 2022016516 A MX2022016516 A MX 2022016516A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- exhibitng
- diones
- pyridine
- mnk
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046325P | 2020-06-30 | 2020-06-30 | |
| PCT/US2021/039982 WO2022006331A2 (en) | 2020-06-30 | 2021-06-30 | Pyridine-1,5-diones exhibitng mnk inhibition and their method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016516A true MX2022016516A (es) | 2023-03-28 |
Family
ID=79315594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016516A MX2022016516A (es) | 2020-06-30 | 2021-06-30 | Piridina-1,5-dionas que exhiben inhibición de proteínas cinasas activadas por mitogenos que interaccionan con cinasas activadas (mnk) y su método de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230286983A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171565A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023533616A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230041715A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116194112A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021300363A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022026275A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183551A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL299512A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016516A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022006331A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4363419A4 (en) * | 2021-06-30 | 2025-06-11 | 4E Therapeutics, Inc. | Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use |
| EP4646266A1 (en) * | 2023-01-04 | 2025-11-12 | 4E Therapeutics, Inc. | Solid state forms of mnk inhibitors |
| WO2026006417A1 (en) * | 2024-06-26 | 2026-01-02 | 4E Therapeutics, Inc. | Formulations of mnk inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012009735A (es) * | 2010-02-26 | 2012-09-12 | Boehringer Ingelheim Int | 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas. |
| RU2014111055A (ru) * | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
| JP2018531266A (ja) * | 2015-10-22 | 2018-10-25 | セルビタ エス.エー. | ピリドン誘導体およびキナーゼ阻害剤としてのその使用 |
| CA3002558A1 (en) * | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
| GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| JP2019510061A (ja) * | 2016-03-31 | 2019-04-11 | サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited | 高脂肪食関連疾患を阻害する方法 |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| EP3870178A4 (en) * | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Crystalline forms of mnk inhibitors |
| CN111484494B (zh) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | 抑制mnk1和mnk2的多环化合物 |
| EP3972593B1 (en) * | 2019-05-23 | 2025-07-02 | Board of Regents, The University of Texas System | Inhibitor of mnk for the treatment of neuropathic pain |
| CN110256432A (zh) * | 2019-06-27 | 2019-09-20 | 诺沃斯达药业有限公司 | 抑制mnk1和mnk2的多环化合物 |
-
2021
- 2021-06-30 WO PCT/US2021/039982 patent/WO2022006331A2/en not_active Ceased
- 2021-06-30 JP JP2023524490A patent/JP2023533616A/ja active Pending
- 2021-06-30 CA CA3183551A patent/CA3183551A1/en active Pending
- 2021-06-30 BR BR112022026275A patent/BR112022026275A2/pt unknown
- 2021-06-30 KR KR1020237003174A patent/KR20230041715A/ko active Pending
- 2021-06-30 US US18/003,829 patent/US20230286983A1/en active Pending
- 2021-06-30 IL IL299512A patent/IL299512A/en unknown
- 2021-06-30 EP EP21831750.1A patent/EP4171565A4/en active Pending
- 2021-06-30 AU AU2021300363A patent/AU2021300363A1/en active Pending
- 2021-06-30 MX MX2022016516A patent/MX2022016516A/es unknown
- 2021-06-30 CN CN202180056845.0A patent/CN116194112A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3183551A1 (en) | 2022-01-06 |
| WO2022006331A9 (en) | 2022-03-03 |
| KR20230041715A (ko) | 2023-03-24 |
| WO2022006331A3 (en) | 2022-02-10 |
| JP2023533616A (ja) | 2023-08-03 |
| WO2022006331A8 (en) | 2023-03-16 |
| EP4171565A4 (en) | 2024-11-27 |
| US20230286983A1 (en) | 2023-09-14 |
| EP4171565A2 (en) | 2023-05-03 |
| CN116194112A (zh) | 2023-05-30 |
| WO2022006331A2 (en) | 2022-01-06 |
| BR112022026275A2 (pt) | 2023-03-14 |
| AU2021300363A1 (en) | 2023-02-09 |
| IL299512A (en) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000028A (es) | Piridin-1,5-dionas espirocíclicas que exhiben inhibición de la proteína cinasa activada por mitógenos (mnk) y su método de uso. | |
| ZA202409114B (en) | MODULATORS OF THR-ß AND METHODS OF USE THEREOF | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| CR20200503A (es) | Inhibidores de cinasa dependientes de ciclina | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| PH12022553024A1 (en) | Inhibitors of nek7 kinase | |
| MX418519B (es) | Inhibidores selectivos de jak1 | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| WO2022006331A8 (en) | Pyridine-1,5-diones exhibiting mnk inhibition and their method of use | |
| MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
| MX2023004033A (es) | Espiro derivados de alfa-d-galactopiranosidos. | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| MX2022015495A (es) | Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2024008868A (es) | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. | |
| PH12022552727A1 (en) | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno |